- $18.91m
- -$46.41m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.33 | ||
| Price to Tang. Book | 3.33 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -88.05% | ||
| Return on Equity | -121.36% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.7 | 33.97 | 3.21 | 1.16 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
Directors
- Kush Parmar NEC (40)
- Arthur Tzianabos PRE (58)
- W. Bradford Smith CFO (65)
- Albert Seymour CSO (53)
- Gabriel Cohn OTH (62)
- Steven Gillis IND (68)
- Richard Gregory IND (63)
- Matthew Patterson IND (49)
- Jeffrey Poulton IND (53)
- Alise Reicin IND (60)
- Mary Thistle IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 12th, 2015
- Public Since
- March 28th, 2018
- No. of Shareholders
- 29
- No. of Employees
- 42
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 12,197,615
- Address
- 830 Winter Street, WALTHAM, 02451
- Web
- https://www.q32bio.com/
- Phone
- +1 7819990232
- Auditors
- Ernst & Young LLP
Upcoming Events for QTTB
Q2 2025 Q32 Bio Inc Earnings Release
Q3 2025 Q32 Bio Inc Earnings Release
Similar to QTTB
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Q32 Bio share price?
As of Today at 22:47 UTC, shares in Q32 Bio are trading at $1.55. This share price information is delayed by 15 minutes.
How has the Q32 Bio share price performed this year?
Shares in Q32 Bio last closed at $1.55 and the price had moved by -94.22% over the past 365 days. In terms of relative price strength the Q32 Bio share price has underperformed the S&P500 Index by -94.66% over the past year.
What are the analyst and broker recommendations for Q32 Bio?
The overall consensus recommendation for Q32 Bio is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Q32 Bio dividend yield?
Q32 Bio does not currently pay a dividend.
Does Q32 Bio pay a dividend?
Q32 Bio does not currently pay a dividend.
When does Q32 Bio next pay dividends?
Q32 Bio does not currently pay a dividend.
How do I buy Q32 Bio shares?
To buy shares in Q32 Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Q32 Bio?
As of the previous close price of $1.55, shares in Q32 Bio had a market capitalisation of $18.91m.
Where are Q32 Bio shares listed?
Here are the trading details for Q32 Bio:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: QTTB
What kind of share is Q32 Bio?
Based on an overall assessment of its quality, value and momentum Q32 Bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Q32 Bio share price forecast for 2025?
The analyst consensus target price for shares in Q32 Bio is $10.00. That is 545.16% above the last closing price of $1.55.
Analysts covering Q32 Bio currently have a consensus Earnings Per Share (EPS) forecast of -$4.18 for the next financial year.
Find out moreWhat is the trend in the Q32 Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Q32 Bio. Over the past six months, its share price has underperformed the S&P500 Index by -96.37%.
As of the last closing price of $1.55, shares in Q32 Bio were trading -92.62% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Q32 Bio PE Ratio?
The Q32 Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.55.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Q32 Bio?
Q32 Bio's management team is headed by:
- Kush Parmar - NEC
- Arthur Tzianabos - PRE
- W. Bradford Smith - CFO
- Albert Seymour - CSO
- Gabriel Cohn - OTH
- Steven Gillis - IND
- Richard Gregory - IND
- Matthew Patterson - IND
- Jeffrey Poulton - IND
- Alise Reicin - IND
- Mary Thistle - IND